Table 3. Results of seroepidemiological investigations for Zika virus according to study sites and time of sampling, Mali.
Study site and year | Total no. | IgG* doubtful, no. (%) | IgG* positive, no. (%) | VNT† positive, no. (%) |
---|---|---|---|---|
Niono 2016 | 65 | 4 (6 0.2) | 4 (6.2) | 2 (3.1) |
Bamako 2016 | 129 | 0 (0.0) | 11 (8.5) | 7 (5.4) |
Bamako 2013‡ | 637 | 18 (2.8) | 67 (10.5) | 47 (7.4) |
Kadiolo 2016 | 136 | 14 (10.3) | 22 (16.2) | 14 (10.3) |
Bougouni 2016 | 127 | 3 (2.4) | 22 (17.3) | 15 (11.8) |
Kita 2016 | 40 | 5 (12.5) | 7 (17.5) | 6 (15.0) |
Bandiagara 2016 | 187 | 24 (12.8) | 81 (43.3) | 29 (15.5) |
Diéma 2016 |
109 |
14 (12.8) |
39 (35.8) |
22 (20.2) |
Total | 1,430 | 82 (5.7) | 253 (17.7) | 142 (9.9) |
*Result by Euroimmun IgG ELISA assay. †Result by cytopathic effect-based virus neutralization test. ‡Volunteer blood donors.